SCHEMBL24975147

SCHEMBL24975147

CC(=O)N(CC1CC1)c1ccc(-c2ccc(C(=O)NCc3cccnc3)cn2)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 3/20 0.46
▸ LMNA P02545 5/20 0.44
▸ RECQL P46063 1/20 0.44
▸ HPGDS O60760 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ HTT P42858 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ MMP13 P45452 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ POLB P06746 2/20 0.42
▸ GLA P06280 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29801000 1.00 NAMPT (0.46) NAMPTLMNARECQLHPGDSALDH1A1
SCHEMBL24975326 0.93 MAPK1 (0.43) LMNARECQLHPGDSALDH1A1HTT
SCHEMBL29801070 0.93 MAPK1 (0.43) LMNARECQLHPGDSALDH1A1HTT
SCHEMBL29801439 0.91 LMNA (0.41) LMNARECQLHPGDSALDH1A1HTT
SCHEMBL24975197 0.91 LMNA (0.41) LMNARECQLHPGDSALDH1A1HTT
SCHEMBL24976682 0.91 CYP3A4 (0.49) NAMPTLMNAHPGDSALDH1A1HTT
SCHEMBL29801235 0.91 NAMPT (0.51) NAMPTLMNAHPGDSALDH1A1HTT
SCHEMBL24975196 0.91 NAMPT (0.51) NAMPTLMNAHPGDSALDH1A1HTT
SCHEMBL24975356 0.89 LMNA (0.48) LMNARECQLHPGDSALDH1A1HTT
SCHEMBL29801250 0.89 LMNA (0.48) LMNARECQLHPGDSALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2023-01-26 — — US disclosed
CN-114929672-A Cancer therapy targeting cancer stem cells 治疗方案股份有限公司 2022-08-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, KIT, GLI1 NAMPT 2789/4885LMNA 2667/4885RECQL 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback